Fluticasone — Intranasal corticosteroid. Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Fluticasone
Class
Intranasal corticosteroid
Mechanism
A synthetic trifluorinated corticosteroid with anti-inflammatory activity. High glucocorticoid-receptor binding affinity is shown in vitro, but its clinical significance and the precise mechanism of rhinitis symptom relief are unknown.
Used for
Nasal symptoms of perennial nonallergic rhinitis in adults and children aged 4 or older
Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260805 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: A synthetic trifluorinated corticosteroid with anti-inflammatory activity and high glucocorticoid-receptor affinity in vitro. It affects inflammatory cells and mediators, but the precise mechanism of rhinitis symptom relief and the clinical significance of receptor-binding findings are unknown.
On both cards: Used for — Nasal symptoms of perennial nonallergic rhinitis in adults and children aged 4 or older · Common side effects — Headache; Pharyngitis; Epistaxis; Nasal burning / irritation; Cough · Warnings — Epistaxis, nasal ulceration, septal perforation; Glaucoma and cataracts
Only on the Fluticasone propionate card: Warnings — Hypercorticism / adrenal suppression · Interactions — Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole)
Mechanism: Corticosteroid with potent anti-inflammatory effects on mast cells, eosinophils, and mediators; exact mechanism in rhinitis unknown.
On both cards: Common side effects — Headache; Pharyngitis; Epistaxis; Cough · Warnings — Glaucoma and cataracts
Only on the Mometasone Furoate (nasal) card: Used for — Prevention of seasonal allergic-rhinitis nasal symptoms in adults and children aged 12 or older; Chronic rhinosinusitis with nasal polyps in adults aged 18 or older · Common side effects — Viral infection · Warnings — Epistaxis, nasal ulcer, septal perforation; Adrenal suppression, slowed growth · Interactions — Strong CYP3A4 inhibitors (e.g., ketoconazole)
Mechanism: Binds with high affinity and selectivity to the CysLT1 receptor, inhibiting physiologic actions of leukotriene D4 in the airway.
On both cards: Common side effects — Headache; Pharyngitis; Cough
Only on the Montelukast card: Used for — Asthma prophylaxis and chronic treatment in patients aged 15 years and older; Prevention of exercise-induced bronchoconstriction in patients aged 15 years and older; Seasonal or perennial allergic rhinitis in patients aged 15 years and older only when alternative therapies are ineffective or not tolerated · Common side effects — Upper respiratory infection; Fever · Warnings — Not for acute asthma attacks; Systemic eosinophilia / Churg-Strauss; Aspirin sensitivity persists
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera